Pablo Cagnoni, Rubius CEO

Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

Ru­bius $RU­BY CEO Pablo Cagnoni is fac­ing a crit­i­cal and close­ly-watched test to­day.

Al­most ex­act­ly a year af­ter watch­ing the biotech’s shares rout­ed af­ter dump­ing their lead pro­gram, Cagnoni of­fered me a look at the first cut of the hu­man da­ta from their cur­rent lead can­cer drug pro­gram for their red blood cell ther­a­peu­tics plat­form. And while all the num­bers are small and the ear­ly da­ta just a snap­shot of what’s to come, it could prove a tough sell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.